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Despite significant progress in our understanding of the etiology, biology and genetics of colorectal cancer, as well as important
clinical advances, it remains the third most frequently diagnosed cancer worldwide and is the second leading cause of cancer
death. Based on demographic projections, the global burden of colorectal cancer would be expected to rise by 72% from 1.8
million new cases in 2018 to over 3 million in 2040 with substantial increases anticipated in low- and middle-income countries.
In this meeting report, we summarize the content of a joint workshop led by the National Cancer Institute and the International
Agency for Research on Cancer, which was held to summarize the important achievements that have been made in our
understanding of colorectal cancer etiology, genetics, early detection and treatment and to identify key research questions that
remain to be addressed.
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Introduction
Colorectal cancer is the third most commonly diagnosed malig-
nancy and the second leading cause of cancer death in the world,
accounting for around 1.8 million new cases and 860 000 deaths
in 2018 [1]. Given current demographic projections, the global
burden of colorectal cancer is anticipated to increase by 72% to
over 3 million new cases and by 82% to 1.6 million cancer deaths
annually by 2040 [1]. The geographic distribution of the colorec-
tal cancer burden varies widely, with more than 50% of all cases
and 42% of all deaths occurring in countries with a very high
human development index (HDI; see Figures 1 and 2). Being one
of the clearest examples of disease transition related to human de-
velopment, rapid increases in both colorectal cancer incidence
and mortality are now being seen in many medium to high HDI
countries, particularly in Eastern Europe, Asia and South
America [1, 2] (see Figure 3). In contrast, colorectal cancer inci-
dence and mortality rates have been plateauing or declining in
many very high HDI countries including the United States,
Australia, and several Western European countries [1, 2]. The
reasons for the recent declining trends in overall incidence in
these countries are not fully understood but may be attributable
to a large extent by early detection and removal of colorectal can-
cer precursors through population-based screening programs.
Concomitant improvements in chemotherapy and radiotherapy
for colorectal cancer are also likely to have contributed to the
declining mortality in these countries [3, 4]. While the incidence
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of colorectal cancer in many very high-HDI countries has
decreased among those older than 50 years, rates in younger indi-
viduals appear to be rising, for reasons that are not clear [5, 6]. In
addition, age-specific incidence of colorectal cancer is higher in
men than in women, and men have poorer survival rates than
women [7]. Although the reasons for this disparity by sex are not
clear, it may reflect differences in exposure to colorectal cancer
risk factors, as well as underlying biology.
Survival following colorectal cancer varies considerably be-
tween countries. While 5-year relative survival is now 65% in
high-income countries settings, it is <50% in low-income
countries [8, 9]. Stage at diagnosis remains the most important
prognostic factor for colorectal cancer. In the United States, 5-
year relative survival is currently 89.8% for patients with local-
ized stage, 71.1% for patients with regional spread, and 13.8%
for patients with metastatic disease at diagnosis [5]. However,
differences can be observed in stage-specific survival even across
high-income countries [10]. Ancestry may also represent an im-
portant factor for both disease incidence and survival—in the
United States, for example, the burden of colorectal cancer
appears to be greatest among African-Americans and is lowest
in Hispanics [7].
ASR (World) per 100000
≥ 26.8
16.8–26.8
10.7–16.8
6.2–10.7 Not applicable
No data< 6.2
Figure 1. Worldwide incidence of colorectal cancer (age standardized rates per 100 000; GLOBOCAN 2018).
ASR (World) per 100000
≥ 11.1
8.6–11.1
6.4–8.6
4.5–6.4 Not applicable
No data< 4.5
Figure 2. Age-standardized rates for colorectal cancer mortality per 100 000 (GLOBOCAN 2018).
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Etiologic risk factors
Colorectal cancer is a complex disease with a significant number
of recognized risk factors. Advancing age, male sex, family history
of colorectal cancer, inflammatory bowel disease, smoking, exces-
sive alcohol drinking, overweight and obesity, low levels of phys-
ical activity and sedentary lifestyle, diabetes and high
consumption of red and processed meat are established risk fac-
tors (Table 1) [11–14]. Individuals with inflammatory bowel dis-
ease or those with first-degree relatives with colorectal cancer
have an approximately twofold higher risk of developing the dis-
ease [15, 16]. Use of menopausal hormone therapy has been asso-
ciated with lower risk of colorectal cancer in observational
studies but findings from subsequent clinical trials have not
shown consistent results [17–19]. Conversely, both observational
studies and trials have demonstrated that nonsteroidal anti-
inflammatory drugs (NSAID) and aspirin specifically can reduce
the risk of colorectal cancer and pre-malignant colorectal adeno-
mas [20–23]. Given the relative safety and high prevalence of
NSAID/aspirin use worldwide, there has been anticipation that
the use of these drugs could offer an effective preventive strategy
for colorectal cancer. In particular, such pharmacologic interven-
tions could be directed toward those at higher risk for this
disease. Currently, trials are underway to examine the effect of as-
pirin administration on colorectal cancer development in both
average-risk populations and among individuals with hereditary
colorectal cancer (e.g. Lynch syndrome) and such a strategy
could be extended to individuals at higher risk because of other
risk factors [24].
Decades of research have focused on dietary factors: some
studies have suggested a protective effect of diets rich in fruit, veg-
etables, fish, fiber and whole grains, calcium and dairy products
against colorectal cancer [11] (Table 1). Epidemiological studies
have also consistently shown an inverse association between cir-
culating vitamin D concentrations and risk of this malignancy
[25], although findings from recent genetic analyses do not sup-
port a causal relationship [26].
Overweight, obesity and type 2 diabetes (T2D) are established
risk factors for colorectal cancer and it has been estimated that
they may account for more than 10% of colorectal cancer cases
worldwide [27–29]. Given the global rising prevalence of obesity
and T2D, these conditions are likely to impact significantly on
colorectal cancer incidence in the coming decades [30, 31].
Important questions remain regarding the underlying mecha-
nisms linking colorectal cancer risk with many of its risk factors.
The application of novel technologies such as metabolomics and
proteomics that can simultaneously identify thousands of bio-
logical features in a single bio-sample hold promise and some
novel insights have been provided by recent analyses [32, 33].
There is a growing body of experimental and observational evi-
dence implicating the gut microbiome in colorectal cancer devel-
opment and progression [34–36]. However, studies linking
variation in the gut microbiome with colorectal cancer in human
studies are still in their infancy. A small case–control study with
available fecal samples demonstrated differences in the relative
distribution of bacterial taxa between colorectal cancer cases and
controls with enrichment of Bacteroidetes and depletion of
Firmicutes [34]. In addition, increased carriage of genera
Fusobacterium, Atopobium and Porphyromonas has also been
associated with colorectal cancer [34, 37]. Fusobacterium are
prevalent in colon tissue and can be observed in distal metastases,
suggesting a possible role in the latter [38]. Atopobium, a Gram-
positive anaerobic bacterium, has been associated with Crohn’s
disease and has been reported to inhibit colonocyte apoptosis
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Figure 3. Trends in colorectal cancer incidence in selected countries. *Regional registries. Source: GLOBOCAN 2018 [1].
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in vitro [37, 39]. These studies are consistent with the concept of
‘dysbiosis’, or microbiotic imbalance, leading to a pro-
inflammatory microenvironment that is conducive to colorectal
tumorigenesis. However, caution is required in the interpretation
of case–control and cross-sectional studies due to the potential of
reverse causality [40]. The prospective, systematic, and standar-
dized collection of fecal samples as well as colorectal tissue speci-
mens within the framework of well-characterized, population-
based cohort studies is required to advance our knowledge on the
etiologic role of the microbiota and possible effects through im-
munity on colorectal tumorigenesis [41].
Molecular pathology
Approximately 95% of presumed colorectal cancers are adeno-
carcinomas, invariably developing over more than 10 years, with
dysplastic adenomas the most common form of premalignant
precursor lesions. A number of different genomic alterations
have been shown to be important for the development of colorec-
tal cancer. Mutations in APC are an early event in the develop-
ment of this cancer, followed by activating mutations of the
KRAS oncogene and inactivating mutations of the TP53 tumor
suppressor gene [42–44]. Molecular characterization of tumors,
including somatic mutations in BRAF and KRAS, microsatellite
instability (MSI), and CpG island methylator phenotype
(CIMP), has provided evidence of multiple tumor subtypes that
develop through activation of diverse neoplastic pathways [42,
43]. More recently, new landscape-style technologies such as
extensive next-generation sequencing as applied in The Cancer
Genome Atlas (TCGA) Project have enabled further characteriza-
tion of the mutational repertoire of colorectal tumors, highlight-
ing mutations in genes such as APC, TP53, SMAD4, PTEN,
RNF43, FBXW7, and PIK3CA as well as in genes that are less well
known, e.g. SOX9, B2M, or ACVR1B; such results indicate the
importance of a complex number of key pathways, including
those of MAPK, Wnt, or TGFb signaling and more recently
immune-modulating pathways [45, 46]. In addition, transcrip-
tomic analyses have permitted the classification of colorectal
tumors into four consensus molecular subtypes (CMS) with dis-
tinct features, namely; CMS1, which accounts for around 14% of
colorectal tumors, exhibit hypermutated status, MSI and strong
immune activation; CMS2 (37%), or the canonical epithelial sub-
type, shows marked Wnt and MYC signaling activation; CMS3
(13%) is characterized by substantial metabolic dysregulation;
and CMS4 (23%) is a mesenchymal subtype that exhibits prom-
inent transforming growth factor-b activation, stromal invasion
and angiogenesis [47]. The integration of data on tumor molecu-
lar features such as genomic alterations and gene expression into
epidemiological studies—a rapidly evolving field known as mo-
lecular pathological epidemiology—offers an opportunity to bet-
ter map the importance of risk factors to specific subtypes of
colorectal cancer [48, 49]. Already some important observations
have been made—e.g. showing that smoking appears to be a spe-
cific risk factor for MSI-high, CIMP-positive and BRAF mutation
positive tumors [50], while aspirin use is associated with lower
mortality in COX2 positive, but not negative, colorectal cancer
[22, 51, 52]. Such an approach may also inform the pathways
Table 1. Major risk factors for colorectal cancer and potential biological mechanisms
Risk factor Association with colorectal cancer Potential mechanisms
Obesity Raises risk: RR per 5 kg/m2 in BMI¼1.08 (95% CI 1.04–
1.11)
Hyperinsulinemia, elevated bioavailable IGF-I; elevated
inflammation
Physical activity Reduction in risk: RR comparing highest with lowest
levels¼0.81 (95% CI 0.69–0.95)
Reduction in insulin and inflammation (long-term); improved im-
mune function
Adult height Raises risk: RR per 5 cm¼1.05 (95% CI 1.04–1.07) Higher IGF-I levels; longer intestines/greater number of cells—
greater opportunity for mutation acquisition
Alcohol Raises risk: RR per 10 g/day¼1.07 (95% CI 1.05–1.09) Elevated acetaldehyde leading to oxidative stress, lipid peroxida-
tion; pro-inflammatory effect; folate deficiency—interference
with one carbon metabolism
Red and processed meat Red meat: increases risk: RR per 100 g/day¼1.12
(95% CI 1.00–1.25); processed meat—increases
risk: RR per 50 g/day¼1.16 (95% CI 1.08–1.26)
Elevated exposure to nitrites; endogenous N-nitroso compound
formation; heme iron exposure; heterocyclic amine (HCA) and
polycyclic aromatic hydrocarbon (PAH) exposure for meats
cooked at high temperature
Fruit and vegetable intake Reduction in risk: RR per 100 g/day¼0.91 (95% CI
0.84–1.00)
Source of vitamins A, C, E; folate as well as other phytochemicals
with potential antitumorigenic properties; fiber
Fiber Reduction in risk: RR per 10 g/day¼0.91 (95% CI
0.84–1.00)
Butyrate and other fermentation products; improved insulin sensi-
tivity; reduced transit time
Dairy foods Reduction in risk: RR per 400 g/day¼0.84 (95% CI
0.80–0.89)
Elevated calcium; vitamin D; changes to gut microbiota (short
chain fatty acids)
Aspirin/NSAIDs Reduction in risk: RR comparing regular versus non-
use¼0.79 (95% CI 0.74–0.85)
Inhibition of COX leads to reduction in inflammation; Inhibition of
NF-kB activation (COX2-independent pathway)—anti-inflam-
matory and antiangiogenic effect
HRT Reduction in risk for ‘current/recent use’ RR¼0.67
(95% CI 0.59–0.77)
Possible antitumorigenic effect of estrogen in colorectal tissue
mediated through ER-b
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linking diet and colorectal cancer development. For example, in a
recent analysis it was demonstrated that the association between
x-3 polyunsaturated fatty acids was restricted to colorectal can-
cers characterized by a specific pattern of tumor-infiltrating T
cells [53]. The integration of tumor molecular pathological data
into large-scale investigations of germline genetic, lifestyle and
environmental risk factors and colorectal cancer risk will likely
yield new insights into the mechanisms of colorectal cancer
development.
Another important consideration in the molecular pathology
of colorectal cancer is the role of the immune system. Within the
tumor microenvironment, both innate and adaptive immune
cells are present and interact with the tumor via direct contact or
through cytokine signaling that shapes the behavior of the tumor
and its response to therapy. In particular, the presence of T cells
in colorectal tumor tissue suggests that the adaptive immune sys-
tem may be activated in colorectal tumorigenesis [54, 55]. Recent
studies have demonstrated that the presence of a lymphocytic im-
mune response in colorectal cancer is associated with more favor-
able patient outcomes [56–58]. However, while the prognostic
implications of such an immune response are increasingly evi-
dent, the factors that modulate that reaction remains unclear. It
is likely that the immune infiltrate is influenced by many factors,
including the tumor microenvironment, tumor genomic altera-
tions and the genetic background of the patient. The gut micro-
biota as well as physical activity, dietary and other exogenous
environmental factors also likely play a role [59–62]. Future re-
search that characterizes interactions between the immune sys-
tem, tumor biology, and environmental factors may uncover
important pathophysiological pathways for colorectal cancer.
Genetic factors
Colorectal cancer has a substantial heritable component, with
large studies of twins suggesting up to 35% of colorectal cancer
risk could be attributable to heritable factors [63]. The two most
common forms of hereditary colorectal cancer are hereditary
nonpolyposis colon cancer (Lynch syndrome) and familial aden-
omatous polyposis (FAP) coli which account for<5% of all colo-
rectal cancer [64, 65]. Both syndromes are autosomal dominant
disorders and follow the molecular pathogenesis typical of colo-
rectal cancer: Lynch syndrome-associated cancers show signs of
mismatch repair deficiency and are consequently MSI-high,
whereas FAP-associated cancers follow the classic adenoma–
carcinoma sequence. Additional rare, but high-penetrance, gen-
etic variants have recently been implicated in colorectal cancer
susceptibility including those in POLE, POLD1, and GREM1
associated with an autosomal dominant pattern of inheritance
and MUTYH, MSH3, and NTHL1 with autosomal recessive in-
heritance [66–69]. However, together these genes account for
<1% of colorectal cancers.
Despite intensive research efforts, the genetic factors that deter-
mine susceptibility to colorectal cancer beyond these hereditary
forms are still incompletely understood. Genome-wide associ-
ation studies (GWAS) have identified an increasing number of
single nucleotide polymorphisms (SNPs) showing statistically
significant but typically very small associations with risk of colo-
rectal cancer. To date, more than 90 common SNPs associated
with colorectal cancer susceptibility have been identified using
genome-wide scans [70–79]. While the observed effect sizes are
small, these discoveries have substantially strengthened and
expanded our understanding of the biological processes underly-
ing the development of this cancer. Genome-wide scans have
implicated biological pathways anticipated to be involved in
colorectal tumorigenesis (e.g. TGF-b, Wnt signaling, p53, PI3K,
MAPK), as well as unexpected pathways (e.g. extracellular matrix
maintenance, laminin gene family, Kru¨ppel-like factors, HLA
genes, Hedgehog signaling genes). These findings can point to
new drug targets both for treating colorectal cancer as well as che-
moprevention in high-risk groups. The identified loci explain
<10% of the relative familial risk, suggesting that, as with other
cancers, a significant number of genetic susceptibility loci remain
to be identified for colorectal cancer. There is now a focus on the
discovery of rare variants and on insertion/deletion polymor-
phisms using exome and whole-genome sequencing approaches.
To date, the majority of GWAS analyses for colorectal cancer
have been conducted in populations of European and Asian des-
cent and there is a paucity of data in African, Hispanic, and other
non-European populations.
Understanding the complex interplay between genetic (G) and
environmental (E) factors in cancer development poses an im-
portant challenge. Increasingly larger GWAS datasets and novel
statistical methods allow for comprehensive ‘agnostic’ genome-
wide GxE interaction scans for colorectal cancer and these have
started to yield novel statistically significant interactions [80–84].
Despite these successes and methodological developments, lim-
ited statistical power due to sample sizes remains a primary chal-
lenge for GxE analyses. Furthermore, the biology underlying the
association of many of the identified genetic variants with colo-
rectal cancer risk remains to be discovered. New technological
approaches, e.g. using normal 3D epithelial colon organoids as
models for testing the interaction between gene function and en-
vironmental factors are now being employed and are expected to
enhance understanding of GxE interaction in colorectal cancer
[85, 86].
Screening and early detection
The majority of colorectal cancers develop from normal epithe-
lium through sequentially worsening degrees of adenomatous
dysplasia. This, together with the strong correlation between
stage at diagnosis and survival, provides the rationale for colorec-
tal cancer screening programs [87]. However, questions remain
regarding the optimal modality of colorectal cancer screening in
terms of specificity, sensitivity, uptake, and economic impact.
The guaiac-based fecal occult blood test (gFOBT) that has been
widely implemented has excellent specificity but poor sensitivity,
particularly for detection of colorectal adenomas. Nevertheless,
screening-based randomized trials using gFOBT have reported
significant reductions in colorectal cancer mortality [87–89].
Fecal immunochemical tests (FIT) for human hemoglobin in
stool have been subsequently developed and are increasingly
used. FIT has higher sensitivity for the detection of colorectal
cancers and its precursors compared with gFOBT [90, 91].
However, no randomized trials of FIT as a screening tool to re-
duce colorectal cancer incidence or mortality have been reported
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thus far. Findings from observational studies are highly consist-
ent with one incidence-based mortality study showing relative
risks of death from colorectal cancer 10%–40% lower among
those screened by FIT [92–94].
Results from a number of randomized trials from the United
States and European countries on the effects of screening by flex-
ible sigmoidoscopy have been published [95–99]. In all of the tri-
als, flexible sigmoidoscopy was associated with a significant
reduction in colorectal cancer incidence and colorectal cancer-
related mortality. Long-term follow-up of the trial from the UK
showed 26% lower colorectal cancer incidence and 30% lower
colorectal cancer mortality after 17 years in those assigned to flex-
ible sigmoidoscopy screening compared with those in the control
arm [99]. In addition, observational data on the association of
endoscopy-based screening with colorectal cancer incidence and
mortality have generally shown consistent risk reductions.
A meta-analysis of observational studies estimated risk reduc-
tions in both incidence and mortality of almost 70% with colon-
oscopy and almost 50% with sigmoidoscopy with a consistently
stronger effect in the distal compared with the proximal colon
[100]. Randomized trials of colonoscopy are currently ongoing
but data on the effect on colorectal cancer incidence or mortality
are not yet available. On the basis of current evidence, national,
and international screening guidelines mostly recommend colo-
rectal cancer screening starting between 50 and 55 years of age for
individuals at average risk, with use of either annual or biennial
gFOBT or FIT, flexible sigmoidoscopy every 5 years, or colonos-
copy every 10 years [101–105]. For individuals at increased risk,
such as first-degree relatives of individuals diagnosed with colo-
rectal cancer at a younger age, initiation of screening at younger
ages is recommended (e.g. starting at age 40 years). For high-risk
groups (FAP, Lynch syndrome, or those with inflammatory
bowel disease) specialized and much more rigorous prevention
programs starting in early life are recommended. Organized colo-
rectal cancer screening programs are yet to be developed and
offered for most countries, however, in many countries with ris-
ing rates of colorectal cancer, screening programs are currently
being evaluated [101]. Finally, recent changes in the guidelines in
some countries, including the United States, now promote the
initiation of screening at a younger age (45 years) for an average
risk population based on modeling studies that support a benefit
in view of the recently observed increase in the incidence rates
of colorectal cancer among individuals younger than 50 years
[106, 107].
Major research efforts are ongoing toward the development of
alternative noninvasive blood or stool-based screening tests, such
as blood-based DNA methylation or protein markers, circulating
colorectal tumor cells (CTCs) and circulating tumor DNA
(ctDNA), as well as stool-based DNA assays [108]. Thus far, these
methods are in preliminary testing stages but it is plausible that
the application of high throughput molecular and cellular meth-
odology may lead to the discovery of highly sensitive biomarkers
with clinical efficacy. Alternative imaging technologies, such as
CT colonography for colorectal cancer screening is also an area of
active exploration [87, 109]. In addition, due to economic con-
straints and low rates of uptake, there is a growing need for strati-
fied or targeted screening. The development of risk prediction
models for colorectal cancer that incorporate demographic, epi-
demiologic as well as genetic data has thus far yielded
discriminative estimates (C-statistics) of 0.6–0.7 [110–113]. It is
anticipated that the incorporation of additional genetic informa-
tion as well as newly discovered biomarkers may eventually im-
prove the efficacy of such models and render them useful for
population-based risk stratification.
Therapy
Until recently, front-line therapy for colorectal cancer has relied
on combination chemotherapy. For example, in high-risk stage II
and III colorectal cancer, a combination of therapies such as 5-
fluorouracil (5-FU), leucovorin and oxaliplatin or capecitabine
with oxaliplatin are administered [114]. For metastatic colorectal
cancer, oxaliplatin or 5-FU/leucovorin/irinotecan are standard
treatment [115]. Profiling of colorectal tumors for RAS muta-
tional status as a prognostic marker and indicator of therapeutic
response has been common practice for some time, however, a
number of biomarkers beyond RAS mutational status are now
emerging which may impact on the response to all classes of new
targeted agents, and specifically for EGFR-antibody therapies.
The era of targeted therapy has widened the horizons for treat-
ment of newly diagnosed and relapsed colorectal cancer. Tests
focused on known recurrent genetic aberrations in colorectal
cancer include HER2, MET and KRAS gene amplification,
ligands such as transforming growth factor-a, amphiregulin
and epiregulin, EGFR mutations and alterations/mutations in
HER3, PI3KCA and PTEN [114]. PIK3CA and PTEN alterations,
which often co-occur with KRAS or BRAF mutations [116], are
also under investigation but there is currently inadequate
evidence for their use as biomarkers of resistance to EGFR-
antibody therapy.
As discussed, the immune system plays a critical role in colo-
rectal cancer development and progression. Immunotherapies
targeting immune checkpoints such as CTLA4, PDCD1 (PD-1),
and CD274 (PD-L1) have led to important advances that have
revolutionized the treatment of many solid tumors [117]. For
colorectal cancer, promising activity has been documented for
immune checkpoint inhibitors in patients with metastatic MSI
high colorectal cancer [118]. Additional trials to determine the
role of immune check point inhibitors in earlier stages of MSI
colorectal cancer or according to other molecular markers are
currently underway. In situ immune cell infiltrate in tumors has
been consistently associated with a favorable prognosis and an
‘immunoscore’ which is derived from a measure of CD3-positive
and CD8-positive density in the tumor is predictive of tumor re-
currence [119]. In a recent multi-national investigation of2650
patients with stage I–III stage colorectal cancer, patients with a
high immunoscore had a statistically significant 60% reduction
in risk of recurrence over the follow-up period and the score was
shown to have greater prognostic value than TMN stage, lympho-
vascular invasion and MSI status [56]. Such a score could prove
invaluable for identifying patients who would benefit from adju-
vant therapies. Future studies should investigate whether the
immunoscore has utility for therapeutic response, as well as go
more deeply in the precise interactions between the tumor and
immune system. New technologies including single-cell tran-
scriptome analysis, and in vivo pathology, will likely improve the
characterization of tumour–immune interactions.
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Multiple tumor-associated antigens have been identified and
utilized for vaccination with varying degrees of success, e.g. carci-
noembryonic antigen, mucin-1, squamous cell carcinoma anti-
gen recognized by T cells 3, as well as p53, all of which have been
employed as targets for immunotherapy in colorectal cancer, as
well as for other tumors [117]. Finally, although CTC number
correlates with prognosis in patients with metastatic colorectal
cancer, the clinical utility of CTC assessments is not yet clear and
therefore cannot be recommended [114, 120]. Similarly, the util-
ity of liquid ctDNA biopsies to guide treatment decisions is cur-
rently under investigation in clinical trials, but cannot yet be
proposed in routine practice.
Discussion
Conclusion
Colorectal cancer is one of the most commonly diagnosed
malignancies worldwide and its incidence is rising in many
countries. There are a number of potentially modifiable risk fac-
tors for colorectal cancer and measures to alter the prevalence
of those risk factors and promote healthy lifestyles could pro-
vide strategies for primary prevention. Several risk factors,
including smoking, excessive alcohol consumption, and obes-
ity, are shared with other common cancers and noncommuni-
cable diseases such as diabetes and cardiovascular disease, and
could be included in comprehensive primary prevention strat-
egies. Improved understanding of the molecular pathogenesis
of colorectal cancer including its etiologic pathways, genetic
determinants and causes of somatic changes, as well as interac-
tions with the immune system and the microbiome, could en-
able more targeted prevention and therapeutic strategies. As has
been shown for cardiovascular disease, substantial progress has
been made in prevention through understanding of etiology
(e.g. dietary and lifestyle changes, statins), rather than treating
advanced disease. Accordingly, it is important to extend our
efforts to gaining mechanistic insight into how certain risk fac-
tors affect colorectal cancer development. The pathogenesis of
colorectal cancer and the relative accessibility of the colorectum
render this malignancy amenable to screening and secondary
prevention. Future efforts should be directed toward identify-
ing population strata that would benefit most from screening
and chemopreventive strategies that could be better tailored to
individual risk assessment, as a realization of precision preven-
tion in oncology.
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Important questions to be prioritized:
1. What factors explain the geographical, racial/ethnic and sex
differences in the incidence of colorectal cancer and what
are the factors driving distinct trends in different
populations?
2. What are the underlying factors driving recent increases in
colorectal cancer incidence in younger adults observed in
several high-income countries? More broadly, what is the
influence of age on risk factors and preventive interventions
for colorectal cancer?
3. What are the specific metabolic pathways that underlie the
association of obesity and diabetes with colorectal cancer?
Can the application of ‘omics’ technologies such as metabo-
lomics and proteomics help uncover relevant pathophysio-
logical mechanisms and identify novel biomarkers of risk
and progression?
4. Can aspirin/NSAIDs or novel chemopreventive agents be
used to prevent colorectal cancer in high risk groups includ-
ing those defined by high penetrance mutations (e.g. Lynch
syndrome patients) and those with specific risk factors (e.g.
obesity)?
5. What is the contribution of the gut microbiota to colorectal
cancer development and can we evaluate this in population-
based studies with pre-diagnostic measurements of the
microbiota?
6. Can we develop a more comprehensive portrait of the colo-
rectal tumor somatic profile and its etiologic origins and
continue to incorporate molecular pathological data into
large-scale epidemiological studies?
7. What is the precise contribution of the immune system to
colorectal tumorigenesis and what factors modulate this
response?
8. Can we continue to define a comprehensive catalog of
germline susceptibility alleles assessed at the population and
family level and explore their interactions with environmen-
tal factors?
9. Can we advance genomic functional analysis to understand
individual susceptibility alleles and pathways in order to
give new insights into biology (early developmental changes,
mechanism of carcinogenesis)?
10. Can we better define the penetrance of high-risk colorectal
cancer alleles by investigating their association with colorec-
tal cancer in different populations and in family and clinic-
based settings?
11. Will it be possible to move toward an integrative model for
colorectal cancer risk in different populations based on epi-
demiologic factors, genetics and biomarkers (including
microbiome) and can this model be of clinical/translational
utility?
12. What are the optimal screening modalities for colorectal
cancer in different countries? How can we best promote up-
take and adherence to high quality screening programs and
can we make screening more efficacious and cost-effective
by targeting to population strata at greater risk?
13. As we acquire greater understanding of colorectal cancer
biology can such insights translate into new therapies and
can we more precisely identify patient strata who would re-
ceive greater benefit from adjuvant therapy?
Special article Annals of Oncology
516 | Gunter et al. Volume 30 | Issue 4 | 2019
References
1. Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394–424.
2. Arnold M, Sierra MS, Laversanne M et al. Global patterns and trends in
colorectal cancer incidence and mortality. Gut 2017; 66(4): 683–691.
3. Murphy CC, Harlan LC, Lund JL et al. Patterns of colorectal cancer care
in the United States: 1990–2010. J Natl Cancer Inst 2015; 107(10). doi:
10.1093/jnci/djv198.
4. Brenner H, Schrotz-King P, Holleczek B et al. Declining bowel cancer
incidence and mortality in Germany: an analysis of time trends in the
first ten years after the introduction of screening colonoscopy. Deutsch
A¨rztebl Int 2016; 113(7): 101–106.
5. Siegel R, Miller KD, Fedewa SA et al. Colorectal cancer statistics, 2017.
CA Cancer J Clin 2017; 67(3): 177–193.
6. Troeung L, Sodhi-Berry N, Martini A et al. Increasing incidence of colo-
rectal cancer in adolescents and young adults aged 15–39 years in
Western Australia 1982–2007: examination of colonoscopy history.
Front Public Health 2017; 5: 179.
7. Murphy G, Devesa SS, Cross AJ et al. Sex disparities in colorectal cancer
incidence by anatomic subsite, race and age. Int J Cancer 2011; 128(7):
1668–1675.
8. Allemani C, Matsuda T, Di Carlo V et al. Global surveillance of trends
in cancer survival 2000-14 (CONCORD-3): analysis of individual
records for 37513025 patients diagnosed with one of 18 cancers from
322 population-based registries in 71 countries. Lancet 2018;
391(10125): 1023–1075.
9. Sankaranarayanan R, Swaminathan R, Brenner H et al. Cancer survival
in Africa, Asia, and Central America: a population-based study. Lancet
Oncol 2010; 11(2): 165–173.
10. Maringe C, Walters S, Rachet B et al. Stage at diagnosis and colorectal can-
cer survival in six high-income countries: a population-based study of
patients diagnosed during 2000-2007. Acta Oncol 2013; 52(5): 919–932.
11. https://www.wcrf.org/dietandcancer/colorectal-cancer (18 December
2018, date last accessed).
12. Johnson CM, Wei C, Ensor JE et al. Meta-analyses of colorectal cancer
risk factors. Cancer Causes Control 2013; 24(6): 1207–1222.
13. Moore SC, Lee IM, Weiderpass E et al. Association of Leisure-time
physical activity with risk of 26 types of cancer in 1.44 million adults.
JAMA Intern Med 2016; 176(6): 816–825.
14. Morris JS, Bradbury KE, Cross AJ et al. Physical activity, sedentary be-
haviour and colorectal cancer risk in the UK Biobank. Br J Cancer 2018;
118(6): 920–929.
15. Taylor DP, Burt RW, Williams MS et al. Population-based family
history-specific risks for colorectal cancer: a constellation approach.
Gastroenterology 2010; 138(3): 877–885.
16. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients
with ulcerative colitis: a meta-analysis of population-based cohort stud-
ies. Clin Gastroenterol Hepatol 2012; 10(6): 639–645.
17. Green J, Czanner G, Reeves G et al. Menopausal hormone therapy and
risk of gastrointestinal cancer: nested case–control study within a pro-
spective cohort, and meta-analysis. Int J Cancer 2012; 130(10):
2387–2396.
18. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al. Estrogen plus
progestin and colorectal cancer in postmenopausal women. N Engl J
Med 2004; 350(10): 991–1004.
19. Simon MS, Chlebowski RT, Wactawski-Wende J et al. Estrogen plus
progestin and colorectal cancer incidence and mortality. J Clin Oncol
2012; 30 (32): 3983–3990.
20. Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to
prevent colorectal adenomas. N Engl J Med 2003; 348(10): 891–899.
21. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to
prevent colorectal adenomas in patients with previous colorectal cancer.
N Engl J Med 2003; 348(10): 883–890.
22. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer
in relation to the expression of COX-2. N Engl J Med 2007; 356(21):
2131–2142.
23. Cook NR, Lee IM, Zhang SM et al. Alternate-day, low-dose aspirin and
cancer risk: long-term observational follow-up of a randomized trial.
Ann Intern Med 2013; 159(2): 77–85.
24. Burn J, Gerdes AM, Macrae F et al. Long-term effect of aspirin on can-
cer risk in carriers of hereditary colorectal cancer: an analysis from the
CAPP2 randomised controlled trial. Lancet 2011; 378(9809):
2081–2087.
25. McCullough ML, Zoltick ES, Weinstein SJ et al. Circulating vita-
min D and colorectal cancer risk: an international pooling project
of 17 cohorts. J Natl Cancer Inst 2019; 111(2): 158–169.
26. Dimitrakopoulou VI, Tsilidis KK, Haycock PC et al. Circulating vita-
min D concentration and risk of seven cancers: Mendelian randomisa-
tion study. BMJ 2017; 359: j4761.
27. Lauby-Secretan B, Scoccianti C, Loomis D et al. International agency
for research on cancer handbook working group. Body fatness and
cancer—viewpoint of the IARC Working Group. N Engl J Med 2016;
375(8): 794–798.
28. Thrift AP, Gong J, Peters U et al. Mendelian randomization study of
body mass index and colorectal cancer risk. Cancer Epidemiol
Biomarkers Prev 2015; 24(7): 1024–1031.
29. Tsilidis KK, Kasimis JC, Lopez DS et al. Type 2 diabetes and cancer: um-
brella review of meta-analyses of observational studies. BMJ 2015; 350:
g7607.
30. Pearson-Stuttard J, Zhou B, Kontis V et al. Worldwide burden of cancer
attributable to diabetes and high body-mass index: a comparative risk
assessment. Lancet Diabetes Endocrinol 2018; 6(2): 95–104.
31. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in
body-mass index, underweight, overweight, and obesity from 1975 to
2016: a pooled analysis of 2416 population-based measurement studies
in 1289 million children, adolescents, and adults. Lancet 2017; 390:
2627–2642.
32. Murphy N, Jenab M, Gunter MJ. Adiposity and gastrointestinal cancers:
epidemiology, mechanisms and future directions. Nat Rev
Gastroenterol Hepatol 2018; 15(11): 659–670.
33. Shu X, Xiang YB, Rothman N et al. Prospective study of blood metabo-
lites associated with colorectal cancer risk. Int J Cancer 2018; 143(3):
527–534.
34. Ahn J, Sinha R, Pei Z et al. Human gut microbiome and risk for colorec-
tal cancer. J Natl Cancer Inst 2013; 105(24): 1907–1911.
35. Zeller G, Tap J, Voigt AY et al. Potential of fecal microbiota for early-
stage detection of colorectal cancer. Mol Syst Biol 2014; 10(11): 766.
36. Zackular JP, Baxter NT, Iverson KD et al. The gut microbiome modu-
lates colon tumorigenesis. mBio 2013; 4: e00692-13.
37. Chen W, Liu F, Ling Z et al. Human intestinal lumen and mucosa-
associated microbiota in patients with colorectal cancer. PLoS One
2012; 7(6): e39743.
38. Bullman S, Pedamallu CS, Sicinska E et al. Analysis of Fusobacterium
persistence and antibiotic response in colorectal cancer. Science 2017;
358(6369): 1443–1448.
39. Manichanh C, Rigottier-Gois L, Bonnaud E et al. Reduced diversity of
faecal microbiota in Crohn’s disease revealed by a metagenomic ap-
proach. Gut 2006; 55(2): 205–211.
40. Amitay EL, Werner S, Vital M et al. Fusobacterium and colorectal can-
cer: causal factor or passenger? Results from a large colorectal cancer
screening study. Carcinogenesis 2017; 38(8): 781–788.
41. Sinha R, Abu-Ali G, Vogtmann E et al. Assessment of variation in mi-
crobial community amplicon sequencing by the Microbiome Quality
Control (MBQC) project consortium. Nat Biotech 2017; 35:
1077–1086.
42. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations
during colorectal-tumor development. N Engl J Med 1988; 319(9):
525–532.
43. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colo-
rectal cancer. Gastrointest Cancer Res 2012; 5(1): 19–27.
44. Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome
landscapes. Science 2013; 339(6127): 1546–1558.
45. Cancer Genome Atlas Network. Comprehensive molecular character-
ization of human colon and rectal cancer. Nature 2012; 487: 330–337.
Annals of Oncology Special article
Volume 30 | Issue 4 | 2019 doi:10.1093/annonc/mdz044 | 517
46. Grasso CS, Giannakis M, Wells DK et al. Genetic mechanisms of im-
mune evasion in colorectal cancer. Cancer Discov 2018; 8(6):
730–749.
47. Guinney J, Dienstmann R, Wang X et al. The consensus molecular sub-
types of colorectal cancer. Nat Med 2015; 21(11): 1350–1356.
48. Ogino S, Stampfer M. Colorectal cancer: the evolving field of molecular
pathological epidemiology. J Natl Cancer Inst 2010; 102(6): 365–367.
49. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological
epidemiology of colorectal neoplasia: an emerging transdisciplinary and
interdisciplinary field. Gut 2011; 60(3): 397–411.
50. Limsui D, Vierkant RA, Tillmans LS et al. Cigarette smoking and colo-
rectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst
2010; 102(14): 1012–1022.
51. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of
colorectal cancer. JAMA 2009; 302(6): 649–658.
52. Gray RT, Cantwell MM, Coleman HG et al. Evaluation of PTGS2
expression, PIK3CA mutation, aspirin use and colon cancer survival
in a population-based cohort study. Clin Transl Gastroenterol 2017;
8(4): e91.
53. Song M, Nishihara R, Cao Y et al. Marine x-3 polyunsaturated fatty
acid intake and risk of colorectal cancer characterized by tumor-
infiltrating T cells. JAMA Oncol 2016; 2(9): 1197–1206.
54. Le DT, Hubbard-Lucey VM, Morse MA et al. A blueprint to advance
colorectal cancer immunotherapies. Cancer Immunol Res 2017; 5(11):
942–949.
55. Grizzi F, Basso G, Borroni EM et al. Evolving notions on immune re-
sponse in colorectal cancer and their implications for biomarker devel-
opment. Inflamm Res 2018; 67(5): 375–389.
56. Pages F, Mlecnik B, Marliot F et al. International validation of the con-
sensus immunoscore for the classification of colon cancer: a prognostic
and accuracy study. Lancet 2018; 391(10135): 2128–2139.
57. Ogino S, Nosho K, Irahara N et al. Lymphocytic reaction to colorectal
cancer is associated with longer survival, independent of lymph node
count, microsatellite instability, and CpG island methylator phenotype.
Clin Cancer Res 2009; 15(20): 6412–6420.
58. Galon J, Costes A, Sanchez CF et al. Type, density, and location of im-
mune cells within human colorectal tumors predict clinical outcome.
Science 2006; 313(5795): 1960–1964.
59. Mima K, Sukawa Y, Nishihara R et al. Fusobacterium nucleatum and T
cells in colorectal carcinoma. JAMA Oncol 2015; 1(5): 653–661.
60. Kalra R, Singh SP, Savage SM et al. Effects of cigarette smoke on im-
mune response: chronic exposure to cigarette smoke impairs antigen-
mediated signaling in T cells and depletes IP3-sensitive Ca(2þ) stores.
J Pharmacol Exp Ther 2000; 293: 166–171.
61. Hussain M, Javeed A, Ashraf M et al. Aspirin and immune system. Int
Immunopharmacol 2012; 12(1): 10–20.
62. Huh JY, Park YJ, Ham M et al. Crosstalk between adipocytes and im-
mune cells in adipose tissue inflammation and metabolic dysregulation
in obesity. Mol Cells 2014; 37(5): 365–371.
63. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and herit-
able factors in the causation of cancer—analyses of cohorts of twins
from Sweden, Denmark, and Finland. N Engl J Med 2000; 343(2):
78–85.
64. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med
2003; 348(10): 919–932.
65. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and fa-
milial colon cancer. Gastroenterology 2010; 138(6): 2044–2058.
66. Palles C, Cazier J-B, Howarth KM et al. Germline mutations in the
proof-reading domains of POLE and POLD1 predispose to colorectal
adenomas and carcinomas. Nat Genet 2013; 45(2): 136–144.
67. Jaeger E, Leedham S, Lewis A et al. Hereditary mixed polyposis syn-
drome is caused by a 40kb upstream duplication that leads to increased
and ectopic expression of the BMP antagonist GREM1. Nat Genet 2012;
44(6): 699–703.
68. Weren RD, Ligtenberg MJ, Kets CM et al. A germline homozygous mu-
tation in the base-excision repair gene NTHL1 causes adenomatous
polyposis and colorectal cancer. Nat Genet 2015; 47(6): 668–671.
69. Adam R, Spier I, Zhao B et al. Exome sequencing identifies biallelic
MSH3 germline mutations as a recessive subtype of colorectal aden-
omatous polyposis. Am J Hum Genet 2016; 99(2): 337–351.
70. Tomlinson I, Webb E, Carvajal-Carmona L et al. A genome-wide asso-
ciation scan of tag SNPs identifies a susceptibility variant for colorectal
cancer at 8q24.21. Nat Genet 2007; 39(8): 984–988.
71. Broderick P, Carvajal-Carmona L, Pittman AM et al. A genome-wide
association study shows that common alleles of SMAD7 influence colo-
rectal cancer risk. Nat Genet 2007; 39(11): 1315–1317.
72. Tenesa A, Farrington SM, Prendergast JGD et al. Genome-wide associ-
ation scan identifies a colorectal cancer susceptibility locus on 11q23
and replicates risk loci at 8q24 and 18q21. Nat Genet 2008; 40(5):
631–637.
73. Houlston RS, Webb E, Broderick P et al. Meta-analysis of genome-wide
association data identifies four new susceptibility loci for colorectal can-
cer. Nat Genet 2008; 40(12): 1426–1435.
74. Houlston RS, Cheadle J, Dobbins SE et al. Meta-analysis of three
genome-wide association studies identifies susceptibility loci for colo-
rectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet 2010;
42(11): 973–977.
75. Jia W-H, Zhang B, Matsuo K et al. Genome-wide association analyses
in East Asians identify new susceptibility loci for colorectal cancer. Nat
Genet 2013; 45(2): 191–196.
76. Peters U, Hutter CM, Hsu L et al. Meta-analysis of new genome-wide
association studies of colorectal cancer risk. Hum Genet 2012; 131(2):
217–234.
77. Peters U, Jiao S, Schumacher FR et al. Identification of genetic suscepti-
bility loci for colorectal tumors in a genome-wide meta-analysis.
Gastroenterology 2013; 144(4): 799–807.e24.
78. Schmit SL, Edlund CK, Schumacher FR et al. Novel common genetic
susceptibility loci for colorectal cancer. J Natl Cancer Inst 2019; 111(2):
146–157.
79. Huyghe JR, Bien SA, Harrison TA et al. Discovery of common and rare
genetic risk variants for colorectal cancer. Nat Genet 2019; 51(1): 76–87.
80. Gauderman WJ, Zhang P, Morrison JL, Lewinger JP. Finding novel
genes by testing G  E interactions in a genome-wide association study.
Genet Epidemiol 2013; 37(6): 603–613.
81. Siegert S, Hampe J, Schafmayer C et al. Genome-wide investigation of
gene-environment interactions in colorectal cancer. Hum Genet 2013;
132(2): 219–231.
82. Hutter CM, Slattery ML, Duggan DJ et al. Characterization of the asso-
ciation between 8q24 and colon cancer: gene-environment exploration
and meta-analysis. BMC Cancer 2010; 10: 670.
83. Hutter CM, Chang-Claude J, Slattery ML et al. Characterization of
gene-environment interactions for colorectal cancer susceptibility loci.
Cancer Res 2012; 72: 2036–2044.
84. Figueiredo JC, Hsu L, Hutter CM et al. Genome-wide diet-gene inter-
action analyses for risk of colorectal cancer. PLoS Genet 10(4):
e1004228.
85. Crespo M, Vilar E, Tsai S-Y et al. Colonic organoids derived from
human induced pluripotent stem cells for modeling colorectal cancer
and drug testing. Nat Med 2017; 23(7): 878–884.
86. Sato T, Clevers H. Growing self-organizing mini-guts from a single in-
testinal stem cell: mechanism and applications. Science 2013;
340(6137): 1190–1194.
87. Lauby-Secretan B, Vilahur N, Bianchini F et al.; International Agency
for Research on Cancer Handbook Working Group. The IARC
Perspective on Colorectal Cancer Screening. N Engl J Med 2018;
378(18): 1734–1740.
88. Shaukat A, Mongin SJ, Geisser MS et al. Long-term mortality after screen-
ing for colorectal cancer. N Engl J Med 2013; 369(12): 1106–1114.
89. Scholefield JH, Moss SM, Mangham CM et al. Nottingham trial of fae-
cal occult blood testing for colorectal cancer: a 20-year follow-up. Gut
2012; 61(7): 1036–1040.
90. Lee JK, Liles EG, Bent S et al. Accuracy of fecal immunochemical tests
for colorectal cancer: systematic review and meta-analysis. Ann Intern
Med 2014; 160: 171.
Special article Annals of Oncology
518 | Gunter et al. Volume 30 | Issue 4 | 2019
91. Brenner H, Tao S. Superior diagnostic performance of faecal immuno-
chemical tests for haemoglobin in a head-to-head comparison with
guaiac based faecal occult blood test among 2235 participants of screen-
ing colonoscopy. Eur J Cancer 2013; 49(14): 3049–3054.
92. Chiu HM, Chen SL, Yen AM et al. Effectiveness of fecal immunochemi-
cal testing in reducing colorectal cancer mortality from the One Million
Taiwanese Screening Program. Cancer 2015; 121(18): 3221–3229.
93. Giorgi Rossi P, Vicentini M, Sacchettini C et al. Impact of screening
program on incidence of colorectal cancer: a cohort study in Italy. Am J
Gastroenterol 2015; 110(9): 1359–1366.
94. Ventura L, Mantellini P, Grazzini G et al. The impact of immunochemi-
cal faecal occult blood testing on colorectal cancer incidence. Dig Liver
Dis 2014; 46(1): 82–86.
95. Schoen RE, Pinsky PF, Weissfeld JL et al. Colorectal cancers not
detected by screening flexible sigmoidoscopy in the prostate, lung, colo-
rectal, and ovarian cancer screening trial. Gastrointest Endosc 2012;
75(3): 612–620.
96. Atkin WS, Edwards R, Kralj-Hans I et al. Once-only flexible sigmoidos-
copy screening in prevention of colorectal cancer: a multicentre rando-
mised controlled trial. Lancet 2010; 375(9726): 1624–1633.
97. Holme Ø, Løberg M, Kalager M et al. Effect of flexible sigmoidoscopy
screening on colorectal cancer incidence and mortality: a randomized
clinical trial. JAMA 2014; 312(6): 606–615.
98. Segnan N, Senore C, Andreoni B et al. Baseline findings of the Italian
multicenter randomized controlled trial of “once-only sigmo
idoscopy”—SCORE. J Natl Cancer Inst 2002; 94(23): 1763–1772.
99. Atkin W, Wooldrage K, Parkin DM et al. Long term effects of once-only
flexible sigmoidoscopy screening after 17 years of follow-up: the UK
Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet
2017; 389(10076): 1299–1311.
100. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy
and screening colonoscopy on colorectal cancer incidence and mortal-
ity: systematic review and meta-analysis of randomised controlled trials
and observational studies. The BMJ 2014; 348(apr09 1): g2467.
101. Schreuders EH, Ruco A, Rabeneck L et al. Colorectal cancer screening:
a global overview of existing programmes. Gut 2015; 64(10):
1637–1649.
102. Koo S, Neilson LJ, Von Wagner C, Rees CJ. The NHS Bowel Cancer
Screening Program: current perspectives on strategies for improvement.
Risk Manag Health Policy 2017; 10: 177–187.
103. European Colorectal Cancer Screening Guidelines Working Group, von
Karsa L, Patnick J et al. European guidelines for quality assurance in
colorectal cancer screening and diagnosis: overview and introduction to
the full supplement publication. Endoscopy 2013; 45(1): 51–59.
104. Alsanea N, Almadi MA, Abduljabbar AS et al. National guidelines for
colorectal cancer screening in Saudi Arabia with strength of recom-
mendations and quality of evidence. Ann Saudi Med 2015; 35(3):
189–195.
105. Siew C, Ng Sunny H. Wong Colorectal cancer screening in Asia. Br Med
Bull 2013; 105(1): 29–42.
106. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-
staging/acs-recommendations.html (18 December 2018, date last
accessed).
107. Wolf AMD, Fontham ETH, Church TR et al. Colorectal cancer screen-
ing for average-risk adults: 2018 guideline update from the American
Cancer Society. CA Cancer J Clin 2018; 68(4): 250–281.
108. Shah R, Jones E, Vidart V et al. Biomarkers for early detection of colo-
rectal cancer and polyps: systematic review. Cancer Epidemiol
Biomarkers Prev 2014; 23(9): 1712–1728.
109. Gandon Y. Screening for colorectal cancer: the role of CT colonography.
Diagn Interv Imaging 2014; 95(5): 467–474.
110. Smith T, Muller DC, Moons KGM et al. Comparison of prognostic
models to predict the occurrence of colorectal cancer in asymptomatic
individuals: a systematic literature review and external validation in the
EPIC and UK Biobank prospective cohort studies. Gut 2018 Apr 3
[Epub ahead of print], doi: 10.1136/gutjnl-2017-315730.
111. Hsu L, Jeon J, Brenner H et al. A model to determine colorectal cancer
risk using common genetic susceptibility loci. Gastroenterology 2015;
148(7): 1330–1339.e14.
112. Dunlop MG, Tenesa A, Farrington SM et al. Cumulative impact of
common genetic variants and other risk factors on colorectal cancer
risk in 42, 103 individuals. Gut 2013; 62(6): 871–881.
113. Jeon J, Du M, Schoen RE et al. Determining risk of colorectal cancer
and starting age of screening based on lifestyle, environmental and gen-
etic factors. Gastroenterology 2018; 154(8): 2152–2164.e19.
114. Labianca R, Nordlinger B, Beretta GD et al. Primary colon cancer:
ESMO clinical practice guidelines for diagnosis, adjuvant treatment and
follow-up. Ann Oncol 2013; 24(Suppl 6): vi64–vi72.
115. Grothey A. Optimizing systemic therapy selection in metastatic colorec-
tal cancer. J Natl Compr Canc Netw 2015; 13(Suppl 5): 682–685.
116. Yang ZY, Wu XY, Huang YF et al. Promising biomarkers for predicting
the outcomes of patients with KRAS wild-type metastatic colorectal
cancer treated with anti-epidermal growth factor receptor monoclonal
antibodies: a systematic review with meta-analysis. Int J Cancer 2013;
133(8): 1914–1925.
117. Basile D, Garattini SK, Bonotto M et al. Immunotherapy for colorectal can-
cer: where are we heading? Expert Opin Biol Ther 2017; 17(6): 709–721.
118. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with
mismatch-repair deficiency. N Engl J Med 2015; 372(26): 2509–2520.
119. Wirta EV, Seppala T, Friman M et al. Immunoscore in mismatch
repair-proficient and –deficient colon cancer. J Pathol Clin Res 2017;
3(3): 203–213.
120. Cohen SJ, Punt CJA, Iannotti N et al. Relationship of circulating tumor
cells to tumor response, progression-free survival, and overall survival
in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(19):
3212–3221.
Annals of Oncology Special article
Volume 30 | Issue 4 | 2019 doi:10.1093/annonc/mdz044 | 519
